All In Biotech

Drug Trial Radar · NCT03931681

A Study of OKI-179 in Patients With Solid Tumors

A Phase 1 Study of OKI-179 as a Single Agent in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

May 8, 2019

Primary completion

Nov 27, 2021

Study completion Nov 27, 2021

Sponsor

Lead sponsor
OnKure, Inc.Industry
Sponsor type
Industry
Collaborators
University of Colorado, Denver
First posted
Apr 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1, single center, open-label study, assessing single agent dose escalation of OKI-179.

Conditions

  • Advanced Solid Tumors

Interventions

  • OKI-179Drug

    OKI-179 single agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)Time frame: 2 years
  2. Determine the safety of the drug according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Cancer Center

    Aurora, Colorado

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.